PortalPublikationenTopotecan Weekly Versus Conventional 5-Day Schedule in Patie...

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

Standard

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. / Sehouli, Jalid; Stengel, Dirk; Harter, Philipp; Kurzeder, Christian; Belau, Antje; Bogenrieder, Thomas; Markmann, Susanne; Mahner, Sven; Mueller, Lothar; Lorenz, Ralf; Nugent, Andreas; Wilke, Jochen; Kuznik, Andreas; Doering, Gabriele; Wischnik, Arthur; Sommer, Harald; Meerpohl, Hans-Gerd; Schroeder, Willibald; Lichtenegger, Werner; Oskay-Oezcelik, Guelten.

in: J CLIN ONCOL, Jahrgang 29, Nr. 2, 2, 10.01.2011, S. 242-248.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sehouli, J, Stengel, D, Harter, P, Kurzeder, C, Belau, A, Bogenrieder, T, Markmann, S, Mahner, S, Mueller, L, Lorenz, R, Nugent, A, Wilke, J, Kuznik, A, Doering, G, Wischnik, A, Sommer, H, Meerpohl, H-G, Schroeder, W, Lichtenegger, W & Oskay-Oezcelik, G 2011, 'Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.', J CLIN ONCOL, Jg. 29, Nr. 2, 2, S. 242-248. https://doi.org/10.1200/JCO.2009.27.8911

APA

Sehouli, J., Stengel, D., Harter, P., Kurzeder, C., Belau, A., Bogenrieder, T., Markmann, S., Mahner, S., Mueller, L., Lorenz, R., Nugent, A., Wilke, J., Kuznik, A., Doering, G., Wischnik, A., Sommer, H., Meerpohl, H-G., Schroeder, W., Lichtenegger, W., & Oskay-Oezcelik, G. (2011). Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J CLIN ONCOL, 29(2), 242-248. [2]. https://doi.org/10.1200/JCO.2009.27.8911

Vancouver

Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J CLIN ONCOL. 2011 Jan 10;29(2):242-248. 2. https://doi.org/10.1200/JCO.2009.27.8911

Bibtex

@article{e06c947bedd74acf8f9719af388303a7,
title = "Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.",
abstract = "Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits and risks with either treatment approach.",
keywords = "Adult, Aged, Aged, 80 and over, Disease-Free Survival, Drug Administration Schedule, Drug Resistance, Neoplasm, Female, Humans, Middle Aged, Ovarian Neoplasms, Peritoneal Neoplasms, Quality of Life, Topoisomerase I Inhibitors, Topotecan",
author = "Jalid Sehouli and Dirk Stengel and Philipp Harter and Christian Kurzeder and Antje Belau and Thomas Bogenrieder and Susanne Markmann and Sven Mahner and Lothar Mueller and Ralf Lorenz and Andreas Nugent and Jochen Wilke and Andreas Kuznik and Gabriele Doering and Arthur Wischnik and Harald Sommer and Hans-Gerd Meerpohl and Willibald Schroeder and Werner Lichtenegger and Guelten Oskay-Oezcelik",
year = "2011",
month = jan,
day = "10",
doi = "10.1200/JCO.2009.27.8911",
language = "English",
volume = "29",
pages = "242--248",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

RIS

TY - JOUR

T1 - Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

AU - Sehouli, Jalid

AU - Stengel, Dirk

AU - Harter, Philipp

AU - Kurzeder, Christian

AU - Belau, Antje

AU - Bogenrieder, Thomas

AU - Markmann, Susanne

AU - Mahner, Sven

AU - Mueller, Lothar

AU - Lorenz, Ralf

AU - Nugent, Andreas

AU - Wilke, Jochen

AU - Kuznik, Andreas

AU - Doering, Gabriele

AU - Wischnik, Arthur

AU - Sommer, Harald

AU - Meerpohl, Hans-Gerd

AU - Schroeder, Willibald

AU - Lichtenegger, Werner

AU - Oskay-Oezcelik, Guelten

PY - 2011/1/10

Y1 - 2011/1/10

N2 - Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits and risks with either treatment approach.

AB - Weekly administration of topotecan (Tw) is less toxic and widely considered a better treatment option than conventional 5-day therapy (Tc) in women with platinum-resistant recurrent ovarian cancer. We conducted a randomized phase II trial (TOWER [Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer]) to better define the ratio between benefits and risks with either treatment approach.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Disease-Free Survival

KW - Drug Administration Schedule

KW - Drug Resistance, Neoplasm

KW - Female

KW - Humans

KW - Middle Aged

KW - Ovarian Neoplasms

KW - Peritoneal Neoplasms

KW - Quality of Life

KW - Topoisomerase I Inhibitors

KW - Topotecan

U2 - 10.1200/JCO.2009.27.8911

DO - 10.1200/JCO.2009.27.8911

M3 - SCORING: Journal article

C2 - 21115872

VL - 29

SP - 242

EP - 248

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 2

M1 - 2

ER -